Login

Switch On Your HIV Smarts.

Why do some HIV drugs cost so much? Pharma, insurers, advocacy groups and consumers weigh in

Why do some HIV drugs cost so much? Pharma, insurers, advocacy groups and consumers weigh in

, by Emily Land

Drug pricing is a complicated issue, with pharmaceutical companies on one side, patient activists on the other, and consumers oftentimes stuck somewhere in the middle. Read More

For people with HIV, what’s next after viral suppression?

For people with HIV, what’s next after viral suppression?

, by Emily Land

Improving quality of life—in addition to helping people get to undetectable—can be a focus of health care models that serve people living with HIV. Read More

Magic mushrooms as therapy for long-term HIV survivors?

Magic mushrooms as therapy for long-term HIV survivors?

, by Emily Land

A small study with long-term HIV survivors in San Francisco will investigate whether an experimental treatment with psilocybin and group therapy can be used to improve mental health and emotional well-being. Read More

HIV remission: more clues, but still many questions

HIV remission: more clues, but still many questions

, by Liz Highleyman

Very early HIV treatment does not cure HIV, but can lead to HIV remission in some people, new studies presented at IAS 2017 show. Read More

Surprising price break for newly-approved hepatitis C drug

Surprising price break for newly-approved hepatitis C drug

, by Liz Highleyman

Two new hepatitis C cure drugs, Mavyret and Vosevi, have been approved by the FDA—offering a shorter course of treatment, for a lower cost. Read More